Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL by unknown
RESEARCH Open Access
Mesenchymal stem cells enhance the
oncolytic effect of Newcastle disease virus
in glioma cells and glioma stem cells via
the secretion of TRAIL
Gila Kazimirsky1, Wei Jiang2, Shimon Slavin3, Amotz Ziv-Av1 and Chaya Brodie1,2*
Abstract
Background: Newcastle disease virus (NDV) is an avian paramyxovirus, which selectively exerts oncolytic effects in
cancer cells. Mesenchymal stem cells (MSCs) have been reported to affect tumor growth and deliver anti-tumor
agents to experimental glioblastoma (GBM). Here, we explored the effects of NDV-infected MSCs derived from
different sources, on glioma cells and glioma stem cells (GSCs) and the mechanisms involved in their effects.
Methods: The glioma cell lines (A172 and U87) and primary GSCs that were generated from GBM tumors were
used in this study. MSCs derived from bone marrow, adipose tissue or umbilical cord were infected with NDV
(MTH-68/H). The ability of these cells to deliver the virus to glioma cell lines and GSCs and the effects of NDV-
infected MSCs on cell death and on the stemness and self-renewal of GSCs were examined. The mechanisms
involved in the cytotoxic effects of the NDV-infected MSCs and their influence on the radiation sensitivity of GSCs
were examined as well.
Results: NDV induced a dose-dependent cell death in glioma cells and a low level of apoptosis and inhibition of
self-renewal in GSCs. MSCs derived from bone marrow, adipose and umbilical cord that were infected with NDV
delivered the virus to co-cultured glioma cells and GSCs. Conditioned medium of NDV-infected MSCs induced
higher level of apoptosis in the tumor cells compared with the apoptosis induced by their direct infection with
similar virus titers. These results suggest that factor(s) secreted by the infected MSCs sensitized the glioma cells to
the cytotoxic effects of NDV. We identified TRAIL as a mediator of the cytotoxic effects of the infected MSCs and
demonstrated that TRAIL synergized with NDV in the induction of cell death in glioma cells and GSCs. Moreover,
conditioned medium of infected MSCs enhanced the sensitivity of GSCs to γ-radiation.
Conclusions: NDV-infected umbilical cord-derived MSCs may provide a novel effective therapeutic approach for
targeting GSCs and GBM and for sensitizing these tumors to γ-radiation.
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Background
Glioblastoma (GBM) remains one of the most malignant
disorders in man with an average survival of 14 months
despite optimal surgery, radiation therapy and temozolo-
mide, which are considered the standard treatment of
choice [1, 2]. Due to the infiltrative/invasive nature of
GBM and the complexity of the brain anatomy tumors
cannot be completely removed in the large majority of
cases [2]. GBMs contain a small population of glioma
stem cells (GSCs) that exhibit treatment resistance
which prevents a complete eradication of tumors cells
and is associated with tumor recurrence [3, 4]. There-
fore, new approaches for targeting resistant glioma cells
and GSCs are urgently indicated to improve the progno-
sis of patients with GBM.
One of the novel approaches for the selective target-
ing of tumor cells is based on the use of oncolytic vi-
ruses [5, 6]. These treatments combined specific tumor
cell lysis by the viruses together with acting as in situ
tumor vaccine [6]. Indeed, the potential use of oncoly-
tic viruses for the treatment of cancer has been re-
ported by several investigators with documentation of
long-term survival of patients considered fully resistant
to other available anti-cancer modalities [7]. Oncolytic
viruses such as herpes simplex virus [8], vaccinia virus
[9] and polio virus [10], have been reported as effective
and selective therapies in GBM. In addition, there have
been a number of reports indicating that Newcastle dis-
ease virus (NDV) also acts as an oncolytic virus in a
number of tumors including GBM [11–16]. NDV is a
well-known poultry virus with anti-neoplastic proper-
ties [17]. The preferential oncolytic activity of NDV to-
ward malignant compared to normal cells is not fully
understood, but has been attributed in part to reduced
interferon secretion by malignant cells in contrast to
normal cells [18]. Other mechanisms associated with
the anti-tumor activity of NDV were also reported such
as activation of the intrinsic death pathway, activation
of the endoplasmic eIF2a kinase PERK and caspase 12,
and the secretion of tumor necrosis factor alpha (TNF-
α) or TNF-related apoptosis-inducing ligand (TRAIL)
from the infected tumor cells [7, 19–22]. Indeed,
TRAIL has been considered as a promising anti-tumor
agent with a strong clinical therapeutic potential [23, 24]
and various studies demonstrated selective apoptotic ef-
fects of TRAIL on tumor cells including glioma cells and
GSCs [25–29].
Administration of oncolytic viruses in clinical trials
for GBM involves intratumoral or intravenous injec-
tions, which are associated with inefficient virus deliv-
ery [30]. One of the alternative approaches that have
been explored for efficient virus delivery is the use of
stem cells, such as mesenchymal stem cells (MSCs), as
delivery vehicles. MSCs exhibit homing abilities to sites
of injury, inflammation and tumors [31–34]. Specific-
ally, MSCs have been shown to migrate to sites of ex-
perimental GBMs and to deliver cytotoxic compounds
that exert anti-tumor effects [31, 32]. MSCs can be
obtained from autologous bone marrow (BM) and adi-
pose (AD) tissues [35, 36] or from allogeneic placenta
and umbilical cord, which then can be used as “off-the-
shelf” cells [37, 38]. These cells can be easily expanded
in vitro and used safely for various therapeutic indica-
tions [39, 40]. Recent studies suggest that despite shar-
ing similar cell surface markers, MSCs that are derived
from different sources exhibit differences in their tran-
scriptome, cytokine profile and biological effects [35].
Therefore, MSCs from various sources can have differ-
ent therapeutic impacts in specific clinical indications.
In view of the broad and selective anti-cancer properties
of NDV [41, 42] and the fact that MSCs migrate actively
to tumor sites and cells including cancer stem cells, we in-
vestigated the potential therapeutic effect of NDV-infected
MSCs on glioma cells and GSCs.
Methods
GSC cultures
All human materials were used in accordance with the
policies of the institutional review board at Henry Ford
Hospital, Detroit, MI, USA. The generation of the GSCs
and their characterization were recently described [43–45].
Briefly, GBM specimens were dissociated in 0.05 %
Trypsin/EDTA for 4 h at room temperature followed by
mechanical dissociation. Cells were maintained in neuro-
sphere medium supplemented with 20 ng/ml epidermal
growth factor (EGF) and 20 ng/ml basic fibroblast growth
factor (FGF-beta) and were examined for the expression of
the stemness markers, CD44, Bmi-1, CD133, Musashi-1,
Sox2 and nestin and self-renewal. All the GSCs employed
in this study were examined for tumorigenic potential in
nude mice or rats as recently reported [43–45].
Mesenchymal stem cell cultures
Bone marrow (BM)-derived MSCs, adipose tissue (AD)-
derived MSCs, and umbilical cord (UC) tissue-derived
MSCs were obtained from ScienCell Research Labora-
tories (Carlsbad, CA, USA) and were characterized and
maintained as previously described [46]. The cells
expressed CD73, CD90 and CD105 and were negative
for CD14, CD34, CD80 and CD45. The different cell
types were also examined for their ability to differenti-
ate to osteoblasts, chondrocytes and adipocytes. The
purity of all the MSC preparations was over 95 %.
Co-culture experiments
For the co-culture experiments, MSCs and glioma cells or
GSCs were plated in transwell plates with a 0.4-μm filter.
In some experiments, conditioned medium of infected
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MSCs was isolated and administered directly to the GSCs
or glioma cells.
NDV infection
Oncolytic NDV (MTH-68) prepared at the Beit Dagan
Institute, Israel was used in all experiments. Cells were
infected with different titers of NDV for 2 h, after which
the cells were washed three times and incubated with
fresh medium.
Real-time PCR analysis
Total RNA was isolated from cultured cells using QIAzol
reagent (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocol. A total of 0.5 μg of RNA was
employed to synthesize cDNA by Thermoscript (Invitro-
gen, Carlsbad, CA, USA) with oligodT primers. Primers,
25 μL of 2× SYBR Green Master Mix (Invitrogen), and
30–100 ng cDNA samples were resuspended in a total
volume of 50 μL PCR amplification solution. Reactions
were run on an ABI Prism 7000 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA). Cycle
threshold (Ct) values were obtained from the ABI 7000
software. The following primers were used: NDV: 5’-TCA
CAGACTCAACTCTTGGG-3’ and 5’-CAGTATGAGGT
GTCAAGTTCTTC-3’ as reported [47]. S12 expression
was determined for each RNA sample as a control.
Self-renewal assay
The formation of secondary neurospheres by GSCs was
measured in cells that were plated in 24-well plates at a
density of 10 cells/well through limiting dilution. The
number of neurospheres/well was determined 2 weeks
later for ten different wells. Spheres that contained more
than 20 cells were scored as described [43–45].
Cell death assays
Three methods were employed to analyze cell death: (1)
measurements of lactate dehydrogenase (LDH) levels in
culture supernatants, (2) caspase3/7 activity, and (3)
expression of total and cleaved PARP by Western blot
analysis. Caspase-3/7 activity in the GSCs was measured
using a caspase-3/7 assay kit (Promega, Madison, WI,
USA) according to the manufacturer’s instructions.
Western blot analysis
Western blot analysis was performed as described. Equal
loading was verified using an anti-β-actin or tubulin
antibodies as described [45, 46].
TRAIL secretion and neutralization
The concentrations of TRAIL ligand in cell superna-
tants were measured using a commercial ELISA kit
from Diaclone Research (Besancon, France), according to
the manufacturer’s instructions. A TRAIL neutralizing
antibody (Abcam, Cambridge, MA, USA; 5 μg/ml)), was
added in some of the experiments 24 h prior to the
addition of the conditioned medium. A corresponding
isotype-matched antibody was used as a control.
Statistical analysis
The results are presented as the mean values ± standard
error of the mean (SE). Data were analyzed using ana-
lysis of variance or a Student's t test with correction for
data sets with unequal variances.
Results
NDV exerts selective oncolytic effects on glioma cells and
GSCs
We first examined the oncolytic effects of NDV on gli-
oma cell lines and GSCs. Cells were infected with in-
creasing titers of NDV and cell death was examined
after 24 and 48 h. As presented in Fig. 1a, NDV in-
duced cell death in both U87 and A172 glioma cell
lines already in 1 multiplicity of infection (MOI) and
plateau levels were obtained at 5 MOI for both cell
lines. In contrast, infection of human astrocytes with 10
MOI of NDV induced only a small degree of cell death
(Fig. 1a). Morphological analysis of the infected cells
demonstrated similar results - increased cell death in
the infected U87 cells with no differences in the cell
morphology of human astrocytes (Fig. 1a).
Although NDV has been reported to exert potent
oncolytic effects on cancer cells, its effects on cancer
stem cells or GSCs has not been described. We therefore
examined the oncolytic effect of NDV on GSCs obtained
from fresh glioma specimens that were previously de-
scribed and reported by us [43, 44, 46, 48]. In these
studies, we employed the two GSCs HF2355 and
HF2359 and examined the effects of NDV infection on
the self-renewal and cell death of these cells. We found
that NDV induced cytotoxic effects on both GSCs albeit
to a different degree (Fig. 1c) as determined by LDH
assay and by PARP cleavage for the HF2359 cells
(Fig. 1d). For both GSCs, NDV exerted a lower cytotoxic
effect compared to the glioma cell lines. Similar results
were obtained for an additional two GSCs (data not
shown). In contrast, no significant cytotoxic effect was
observed in human neural stem cells (NSCs) even at 10
MOI and after 72 h (Fig. 1c).
The cytotoxic effect of NDV was also observed on the
stemness characteristics of the GSCs including smaller
neurosphere size (Fig. 1e) and inhibition of self-renewal
of these cells (Fig. 1f ). Using secondary neurosphere for-
mation assay, we found that after 10 days NDV at MOI
of 1 significantly decreased the neurosphere size (Fig. 1e)
and the self-renewal of the GSCs (Fig. 1f ).
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Conditioned medium of NDV-infected MSCs enhances the
virus cytotoxic effect
MSCs have been reported to deliver oncolytic viruses to
various tumors including glioma [16]. To examine the
ability of MSCs to deliver NDV to glioma cells we first
analyzed the infection of the different MSCs by NDV.
For these experiments, we employed MSCs derived from
BM, AD and umbilical cord (UC) tissues. We found that
infection of the MSCs with NDV induced some cell
death after 4 days (around 25–40 %, depending on the
MSC source, Fig. 2a) and a more pronounced effect after
5 days (data not shown).
We then examined the ability of MSCs to deliver NDV
to glioma cells or GSCs using co-cultures plated in
transwell plates with a 0.4-μm filter that does not allow
cell transfer or by using MSC-conditioned medium.
We first demonstrated that MSCs were able to de-
liver NDV to co-cultured glioma cells, as indicated
by the detection of NDV in the glioma cells using
qRT-PCR (Fig. 2b). We did not find a significant dif-
ference in the ability of the different MSCs to in-
crease NDV expression in the glioma cells. Similar
results were obtained with co-cultured GSCs (data
not shown).
As presented in Fig. 2c, co-culturing of glioma cells
with MSCs infected with NDV induced a larger degree
of cell death in the glioma cells compared to cells dir-
ectly infected with the same virus titer. Thus, infection
of A172 cells with 2 MOI NDV induced about 20 %
cell death, whereas co-culturing of A172 cells with
NDV-infected BM-MSCs induced over 40 % cell death.
Similar results were obtained also with AD-MSCs.
Fig. 1 NDV induces a selective cell death in glioma cells and glioma stem cells. The glioma cell lines, U87 and A172 or human astrocytes were
infected with different titers of NDV and cell death was determined using LDH release into the culture supernatants after 48 h (a). The
morphology of U87 cells and human astrocytes was analyzed following NDV infection (2 MOI) using phase contrast microscopy (b). Cell death
was also analyzed in two GSC cultures and human NSCs using LDH assay (c) and in the HF2355 cells using Western blot analysis of cleaved PARP
expression (d). Infection with NDV induced disaggregation of the GSC spheroids (e). The self-renewal of the infected GSCs was determined after
14 days of infection (1 MOI) (f). The results are presented as means ± SE and represent three different experiments (a, c). *p < 0.001 (control vs.
infected cells). One representative of three similar experiments is presented (b, d-f). MOI multiplicity of infection, NDV Newcastle disease virus, NSC
neural stem cell
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Interestingly UC-MSCs infected with NDV induced
the largest cytotoxic effect of glioma cells as compared
with the other types of MSCs. Similar effects were ob-
served with conditioned medium of the infected MSCs
(data not shown). The increased cytotoxic effect of
conditioned medium derived from NDV-infected
MSCs was also observed in GSCs as compared to their
lowered response to direct infection with NDV
(Fig. 2d). Similar effects were obtained with measure-
ments of caspase 3/7 activity in both A172 cells
(Fig. 2e) and the HF2355 GSCs (Fig. 2f ).
The increased cytotoxic effect of NDV-infected MSCs is
mediated by TRAIL
We next analyzed the factors that mediate the enhanced
cytotoxic effects of NDV-infected MSCs on glioma cells
and GSCs. Using ELISA of infected MSC-conditioned
medium we found that control UC cells secreted low
levels of TRAIL and that all infected MSCs secreted in-
creased TRAIL levels, with UC-MSCs demonstrating the
highest levels (Fig. 3a).
To further examine if the increased TRAIL secretion
mediated the enhanced cytotoxic effect of the infected
Fig. 2 Conditioned medium of NDV-infected MSCs exerts potent cytotoxic effects on glioma cells and GSCs. MSCs derived from BM, AD or UC tis-
sue were infected with NDV (5 MOI) and cell death was determined after 3 days using LDH assay (a). MSCs were infected with NDV (2 MOI),
washed three times and co-cultured with A172 cells in transwell plates with 0.4 μm for 48 h. The A172 cells were washed three times and the
presence of NDV in the cells was determined using RT-PCR (b). The A172 cells (c, e) or HF2355 GSCs (d, f) were either infected with 2 MOI NDV
or incubated with medium conditioned from control or NDV-infected MSCs for 2 days. Cell death was determined using LDH assay (c, d) or cas-
pase 3/7 activity assay (e, f) after 24 h. The results are presented as means ± SE and represent three different experiments. *p < 0.001 (control vs.
infected cells). AD adipose tissue, BM bone marrow, GSC glioma stem cell, MSC mesenchymal stromal cells cell, NDV Newcastle disease virus, NSC
neural stem cell, UC umbilical cord
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MSCs we first analyzed the combined effect of TRAIL
and NDV on cell apoptosis of glioma cells and GSCs. As
demonstrated in Fig. 3b, NDV (1 MOI) sensitized glioma
cells to the apoptotic effects of low concentrations of
TRAIL (25 ng/ml), that by itself induced only a marginal
degree of cell death (Fig. 3b). Similarly, NDV also sensi-
tized the GSCs, HF2359 (Fig. 3c) and HF2355 (Fig. 3d)
to the apoptotic effects of TRAIL. A neutralizing anti-
TRAIL antibody partially inhibited the increased cytotoxic
effect of conditioned medium of NDV-infected UC-MSCs
on A172 cells (Fig. 3e), suggesting that TRAIL secreted by
the infected cells mediated this increased effect. Similar
results were obtained with the HF2355 and HF2359 GSCs
(data not shown).
In contrast, human astrocytes and the NSCs did not
exhibit significant cell death in response to either TRAIL,
conditioned medium of NDV-infected UC-MSCs or the
combination of both treatments (data not shown).
Altogether, these results implicate TRAIL as an im-
portant factor secreted by infected MSCs that can aug-
ment the cytotoxic effect of NDV on glioma cells and
GSCs.
Conditioned medium from NDV-infected MSCs sensitize
glioma stem cells to γ-radiation
γ-radiation is the first-line treatment for GBM patients;
however, GSCs have been reported to exhibit increased
resistance to this treatment [49]. Combined treatment of
GSCs with γ-radiation and TRAIL induced increased
cytotoxic effects [27, 50]. We therefore examined the ef-
fect of conditioned medium of NDV-infected MSCs on
the response of GSCs to γ-radiation. As presented in
Fig. 4a, the HF2355 GSCs exhibited a small decrease in
self-renewal in response to γ-radiation treatment (3 Gy)
and this response was further increased in NDV-infected
cells (1 MOI). Similar results were also obtained with
the HF2414 and HF2359 GSCs (data not shown). The
effects of γ-radiation and NDV on cell death in these
cells were very modest (Fig. 4b). In contrast, we found
that a combined treatment of conditioned medium from
UC-MSCs infected with NDV and γ-radiation exerted a
pronounced effect on cell death as compared to each
treatment alone and as was measured by LDH assay
(Fig. 4d) and caspase3/7 activity (Fig. 4c). These results
suggest that conditioned medium derived from NDV-
Fig. 3 NDV-infected MSCs exert an increased cytotoxic effect on glioma cells and GSCs via the secretion of TRAIL. MSCs were infected with NDV
(2 MOI) for 2 days and the levels of secreted TRAIL was determined by ELISA (a). Treatment of A172 (b), the HF2359 GSCs (c) or the HF2355 (d)
with TRAIL (25 ng/ml) and NDV (1 MOI) induced an increased effect on cell death. The addition of a neutralizing anti-TRAIL antibody (5 μg/ml)
prior to NDV infection abrogated the increased cytotoxic effect of conditioned medium derived from UC-MSCs infected with NDV (e), whereas it
did not affect the cytotoxic effect of NDV infection of glioma cells. The results are presented as mean ± SE and represent three different experiments.
*p < 0.001 (control vs. infected cells; NDV + TRAIL vs. NDV and TRAIL; control antibody vs. anti-TRAIL antibody). AD adipose tissue, BM bone marrow,
GSC glioma stem cell, MSC mesenchymal stromal cells cell, NDV Newcastle disease virus, NSC neural stem cell, TRAIL TNF-related apoptosis-inducing
ligand, UC umbilical cord
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infected MSCs can sensitize GSCs to the cytotoxic effects
of γ-radiation.
We also examined if TRAIL secreted by the NDV-
infected UC-MSCs mediated the increased cytotoxic ef-
fect of UC-MSC conditioned medium and γ-radiation.
Using the neutralizing anti-TRAIL antibody that was
employed in the experiments presented in Fig. 3e, we
demonstrated that the secretion of TRAIL by the NDV-
infected UC-MSCs played at least a partial role in
enhancing the response of the GSCs to γ-radiation
(Fig. 4d).
Discussion
In this study, we examined the effects of NDV-infected
MSCs from different sources on glioma cells and GSCs
and the mechanisms involved in their effects.
NDV has been reported to induce selective apoptosis
of various cancer cell lines including glioma [11, 14, 16,
51]; however, its effects on human astrocytes have not
been examined. We demonstrated that infection of U87,
U251 and A172 cells with NDV induced cell apoptosis
already at 1 MOI and that normal human astrocytes
were resistant to the cytotoxic effect of NDV even at 10
MOI, further suggesting that NDV effects are tumor cell
selective.
GBMs contain a population of GSCs that contribute to
therapy resistance and tumor recurrence despite suc-
cessful surgical removal of visible tumor [52]. Thus,
identifying treatments that can selectively target these
cells is of utmost importance in the treatment of GBM.
Our results show for the first time that NDV can also
target GSCs and that although these cells are less sensi-
tive than differentiated tumors cells to the cytotoxic ef-
fect of NDV, they exhibit a decreased self-renewal ability
when infected with low virus titers. Importantly, also for
these cells, the effects of NDV appear to be tumor se-
lective and human NSCs are resistant to NDV infection
as indicated in Fig. 1c.
MSCs have been reported to migrate to tumor sites,
such as glioma, and to deliver various anti-cancer treat-
ments including oncolytic viruses [31, 32, 53–55]. Our
results indicate that MSCs can be also used to deliver
oncolytic NDV to glioma cells and GSCs. We found that
NDV infected the different MSCs and that these cells
Fig. 4 Combined treatment of GSCs with conditioned medium derived from NDV-infected UC-MSCs and radiation exerts a synergistic cytotoxic
effect on GSCs. The HF2355 GSCs were infected with NDV and irradiated (3 Gy) (a). The self-renewal of the cells was determined after 10 days of
treatment. HF2355 GSCs were irradiated in the presence or absence of conditioned medium derived from NDV-infected UC-MSCS (b, c). Cell
death was determined after 3 days using LDH (b) or caspase 3/7 (c) assays. The role of TRAIL in the increased sensitization to radiation was
examined in the HF2359 GSCs. The addition of a neutralizing anti-TRAIL antibody (5 μg/ml) prior to NDV infection and γ-irradiation abrogated
the increased cytotoxic effect of the infected UC-MSCs conditioned medium and that of the combined effects of γ-radiation and the conditioned
medium. Cell death was measured using LDH assay and data are presented as relative cell death (d). The results are presented as the means ± SE and
represent three different experiments. *p < 0.001; **p < 0.01. (*Control vs. infected cells; radiation + CM of NDV-infected UC-MSCs vs. radiation or NDV
alone; control vs. anti-TRAIL antibody; **GSCs treated with UC-MSC CM and NDV infected GSCs vs. untreated cells). MSC mesenchymal stromal cells cell,
NDV Newcastle disease virus, TRAIL TNF-related apoptosis-inducing ligand, UC umbilical cord
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underwent apoptosis after 4 days of infection and in re-
sponse to higher virus titers as compared to glioma
cells. These results suggest that NDV-infected MSCs
can deliver the virus effectively and can be used safely
for the eradication of NDV-sensitive GSCs with no re-
sidual presence of MSCs that could theoretically inhibit
the local immune response elicited by the infected cells
[5, 30].
Interestingly, treatment of glioma cell lines and GSCs
with conditioned medium of NDV-infected MSCs in-
duced a larger cytotoxic effect as compared to glioma
cells infected with similar NDV titers. The most pro-
nounced effect was obtained with UC-MSC infected
cells compared with BM and AD-derived MSCs. We
found that the infected UC-MSCs secreted high levels of
TRAIL and that treatment of glioma cells with condi-
tioned medium of NDV-infected UC-MSCs in the pres-
ence of anti-TRAIL neutralizing antibody abrogated the
enhanced cytotoxic effect of the conditioned medium.
Moreover, infection of glioma cells and GSCs with NDV
sensitized these cells to the apoptotic effect of TRAIL,
further supporting our conclusion that this factor medi-
ated at least some of the enhanced cytotoxic effects of the
NDV-infected MSCs on glioma cells.
TRAIL has been reported to induce a selective cell
apoptosis in tumor cells and has been considered a
promising anti-tumor agent [23, 29]. Indeed, multiple
studies demonstrated the apoptotic effect of TRAIL on
a variety of tumor cells including glioma cells [25–28,
56]. Despite the selective effects of TRAIL on tumor
cells there are some cells (in particular cancer stem
cells) that exhibit resistance to the apoptotic effect of
this ligand [57]. Thus, the current results that demon-
strate an increased cytotoxic effect of TRAIL and NDV
in both glioma cells and GSCs may provide a mechan-
ism to bypass the relative resistance of GSCs to both
TRAIL and NDV. Indeed, a recent study demonstrated
enhanced anti-tumor effects of NDV engineered to ex-
press TRAIL and IL-2 [58, 59]. The delivery of TRAIL
by MSCs engineered to overexpress this protein was
recently reported to exert cytotoxic effects in glioma
xenografts [60, 61]. Our findings demonstrate a novel
approach to increase the secretion of endogenous TRAIL
by NDV infection of UC-MSCs, which may further en-
hance the anti-tumor effects of these cells as was recently
reported [62, 63].
Our results of sensitizing GSCs to γ-radiation by the con-
ditioned medium of NDV-infected MSCs demonstrated a
mechanism to overcome the resistance of GSCs to radi-
ation, which is one of the first-line treatments for
GBM. Indeed, a combined treatment of TRAIL and γ-
radiation has been reported to exert a synergistic effect
in vitro and in vivo [50]. Importantly, recent studies
demonstrated that radiation increased the homing of
MSCs to glioma xenografts [50], therefore suggesting
that not only NDV-infected MSCs are expected to
home to the tumor site more efficiently, but they can
also enhance the response of resistant tumor cells to γ-
radiation.
Considering the preferential migration of MSCs to
tumor sites, it seems reasonable to hypothesize that
using MSCs as a delivery system is likely to provide an
effective method for the selective targeting of NDV to
glioma cells and GSCs. Thus, encapsulating NDV in
MSCs can overcome the current limitations in virus de-
livery and lack of extravasion into the tumor and can
shield the viruses from sequestration in the liver and
neutralization. Since treatment of GBM patients with
NDV seems to be effective in a small fraction of cases
[64], it seems reasonable to assume that a more efficient
transfer of NDV into the tumor cells may result in a
more effective anti-cancer impact for a larger number of
patients. Thus, a targeted delivery of NDV by MSCs may
represent a substantially more effective approach for
transfer of NDV into the malignant cells, rather than
relying on random delivery of the circulating viruses.
Preliminary clinical studies suggest that treatment with
NDV is safe [16]. Similarly, recent preclinical and clin-
ical studies using both autologous and allogeneic MSCs
from various sources indicate that treatment of patients
with various neurological and inflammatory disorders is
safe and has some therapeutic impact [65–69]. Based on
these studies and our results showing the lack of toxicity
of NDV or MSCs loaded with NDV on normal astro-
cytes and NSCs, we expect that treatment with MSCs
loaded with NDV is also likely to be harmless against
normal neural cells in vivo. Thus, infection of MSCs
with NDC may represent a novel approach for the treat-
ment of minimal residual disease and the eradication of
GSCs following or along with conventional modalities.
Conclusions
The infection of UC-MSCs with oncolytic viruses such
as NDV can provide a new therapeutic strategy by com-
bining the homing ability of MSCs towards tumor sites
and the increased secretion of factors with anti-tumor
activity such as TRAIL from the infected cells. Thus,
using NDV-infected MSCs is expected to result in tar-
geted delivery of the virus to tumor cells and enhanced
anti-tumor effects in both glioma cells and GSCs. In
addition, the presence of the infected cells may enhance
the local immune response at the tumors sites as was
reported for cells infected with other viruses [70]. NDV-
infected umbilical cord-derived MSCs may therefore
provide a novel effective therapeutic approach for target-
ing GSCs and GBM and for sensitizing these tumors to
γ-radiation.
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